BioAdaptives, Inc. (BDPT) Stock Analysis

BioAdaptives, Inc. (BDPT) Consumer Business Overview

BioAdaptives, Inc. focuses on marketing and distributing natural health and wellness products, including dietary supplements for both humans and animals. Operating within the consumer defensive sector, the company offers a range of plant and algal-based products, distinguishing itself through specialized formulations like PrimiCell and Canine Regen.

What Is the Investment Thesis for BDPT?

BioAdaptives, Inc. presents a unique investment opportunity within the consumer defensive sector, driven by its focus on natural and plant-based health products. With a small market capitalization, the company exhibits high growth potential, albeit accompanied by significant risk. Key value drivers include expanding its product line and increasing distribution channels for both human and animal supplements. The company's high gross margin of 307.0% suggests strong pricing power, but its negative profit margin of -14090.0% indicates substantial operational inefficiencies that need to be addressed. Upcoming catalysts include potential partnerships to broaden market reach and new product launches targeting specific health needs. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and disclosure.

Based on FMP financials and quantitative analysis

BDPT Key Highlights

Gross Margin of 307.0% indicates strong pricing power on its product offerings.

• Negative Profit Margin of -14090.0% highlights significant operational inefficiencies and high expenses relative to revenue.
• Beta of 1.14 suggests the stock is slightly more volatile than the market.
• The company operates with only 1 employee, indicating a highly lean operational structure.
• Focus on natural plant and algal-based products aligns with growing consumer interest in health and wellness.

Who Are BDPT's Competitors?

BDPT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BDPT's Key Strengths?

Unique plant and algal-based formulations.

• High gross margin indicates strong pricing power.
• Focus on growing natural health market.
• Specialized products for human and animal health.

What Are BDPT's Weaknesses?

Negative profit margin indicates operational inefficiencies.

• Limited brand awareness and market reach.
• High dependence on a small number of products.
• Small company size limits resources for marketing and distribution.

What Could Drive BDPT Stock Higher?

Potential partnerships with distributors to expand market reach.

• New product launches targeting specific health needs.
• Increased online marketing efforts to drive direct-to-consumer sales.
• Research and development of innovative formulations.
• Expansion into new geographic markets.

What Are the Key Risks for BDPT?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

• Competition from larger, more established companies in the dietary supplement market.
• Regulatory changes affecting the sale and marketing of health products.
• Supply chain disruptions and raw material cost increases.
• Limited financial resources and operational inefficiencies.
• Dependence on a small number of products for revenue.

What Are the Growth Opportunities for BDPT?

• Expansion of Product Line: BioAdaptives can grow by introducing new health and wellness products targeting specific consumer needs. The market for personalized nutrition is expanding, with a projected value of $16.93 billion by 2028. Developing specialized formulations and targeted supplements could attract new customers and increase revenue. The timeline for new product launches is estimated at 12-18 months, requiring investment in R&D and regulatory approvals.
• Strategic Partnerships: Forming partnerships with established distributors and retailers can significantly expand BioAdaptives' market reach. Collaborating with veterinary clinics and equine centers could boost sales of animal health products. The global animal health market is projected to reach $53.5 billion by 2027. Strategic alliances can be established within the next 6-12 months, providing immediate access to broader customer base.
• E-commerce Optimization: Enhancing the company's online presence and e-commerce capabilities can drive direct-to-consumer sales. Investing in digital marketing and improving the user experience on its website can attract new customers and increase online sales. The global e-commerce market is expected to reach $6.3 trillion in 2024. Improvements can be implemented within 3-6 months, leading to immediate gains in online visibility and sales.
• Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can unlock significant growth opportunities. These regions have a growing demand for natural health products and dietary supplements. The Asia-Pacific dietary supplements market is projected to grow at the highest CAGR during the forecast period. Market entry strategies can be developed within 12-24 months, requiring careful planning and regulatory compliance.
• Clinical Validation: Conducting clinical trials to validate the efficacy of its products can enhance credibility and attract more customers. Scientific evidence supporting the health benefits of its supplements can differentiate BioAdaptives from competitors. The market for evidence-based supplements is growing, with consumers increasingly seeking products backed by scientific research. Clinical trials can be initiated within 18-24 months, providing long-term competitive advantage.

What Threats Does BDPT Face?

• Competition from larger, more established companies.
• Changing consumer preferences and regulatory requirements.
• Supply chain disruptions and raw material cost increases.
• Economic downturn affecting consumer spending on discretionary items.

What Are BDPT's Competitive Advantages?

• Proprietary Formulations: Unique blend of plant and algal-based ingredients in its products.
• Brand Reputation: Growing recognition for natural and effective health solutions.
• Customer Loyalty: Repeat purchases from satisfied customers.
• Specialized Products: Niche market focus on specific health needs.

What Does BDPT Do?

BioAdaptives, Inc., formerly APEX 8 Inc., was incorporated in 2013 and is headquartered in Las Vegas, Nevada. The company formulates, markets, and distributes natural plant and algal-based products aimed at improving health and wellness for both humans and animals. Its product line includes dietary supplements such as PrimiCell, PluriPain, PrimiLungs, PrimiLive, and PrimiSleep, designed to address various health needs. For the animal market, BioAdaptives offers Canine Regen and Equine Regen, targeting the health and performance of dogs and horses. These products are sold directly to consumers, as well as to trainers, horse owners, and boarding stables. BioAdaptives also markets the Lung Flute for human respiratory health. The company's All-in-One products combine essential minerals, vitamins, amino acids, and botanicals with their proprietary Regen compounds, providing comprehensive nutritional support. BioAdaptives operates within the consumer defensive sector, specifically focusing on packaged foods and dietary supplements, emphasizing natural and plant-based ingredients to cater to health-conscious consumers.

What Products and Services Does BDPT Offer?

• Develops and markets natural plant and algal-based products.
• Offers dietary supplements for human health and wellness.
• Provides animal health products for dogs and horses.
• Markets specialized formulations like PrimiCell, PluriPain, and Regen compounds.
• Distributes products directly to consumers and through partners.
• Focuses on health-conscious consumers seeking natural alternatives.

How Does BDPT Make Money?

• Formulates and manufactures plant and algal-based health products.
• Sells products directly to consumers through online channels.
• Distributes products through partnerships with retailers and distributors.
• Generates revenue from the sale of dietary supplements and animal health products.

What Industry Does BDPT Operate In?

BioAdaptives, Inc. operates within the consumer defensive sector, specifically in the packaged foods and dietary supplements market. This sector is characterized by relatively stable demand, as consumers continue to purchase essential goods regardless of economic conditions. The global dietary supplements market is projected to reach $230.73 billion by 2027, growing at a CAGR of 9.6% from 2020. BioAdaptives competes with larger, more established companies, as well as smaller niche players. Key competitive factors include product innovation, marketing effectiveness, and distribution capabilities. The company's focus on natural and plant-based ingredients positions it to capitalize on the growing consumer preference for healthier and more sustainable products.

Who Are BDPT's Key Customers?

• Health-conscious individuals seeking natural supplements.
• Pet owners looking for natural health solutions for their animals.
• Trainers, horse owners, and boarding stables.
• Consumers interested in preventative health and wellness.

Over the past six months, BioAdaptives, Inc. insiders filed 6 SEC Form 4 transactions — 0 sales and 6 purchases. On net that is roughly 77K shares acquired (about $0) — insiders putting money in tends to read as conviction.

BioAdaptives, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Return on equity for BioAdaptives, Inc. stands at 85.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.05 means current liabilities exceed short-term assets, a liquidity point worth watching.

BDPT Revenue & Earnings Trend

In Jun 2026, BDPT generated $5K in top-line revenue, marking a sequential decrease of 9.5%. The company recorded net income of $150K, with diluted EPS of $0.01. Revenue has contracted over three consecutive quarters, which investors in this unknown Consumer Defensive stock should monitor closely. Across the four most recent quarters, BDPT averaged $-0.03 in diluted EPS.

Company Profile

BioAdaptives, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO James Keener. BDPT has traded publicly since 2016.

BDPT Financials

BDPT Latest News

BDPT Analyst Consensus

BDPT MoonshotScore

BDPT Consumer Defensive Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources